Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors

Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors

Gemcitabine is widely used for pancreatic, lung, and bladder cancer. However, drug resistance against gemcitabine is a large obstacle to effective chemotherapy. Nucleoside transporters, nucleoside and nucleotide metabolic enzymes, and efflux transporters have been reported to be involved in gemcitab...

Full description

Bibliographic Details
Main Authors: Kentaro Minami, Yoshinari Shinsato, Masatatsu Yamamoto, Homare Takahashi, Shaoxuan Zhang, Yukihiko Nishizawa, Sho Tabata, Ryuji Ikeda, Kohich Kawahara, Kazutake Tsujikawa, Kazuo Chijiiwa, Katsushi Yamada, Shin-ichi Akiyama, Sandra Pérez-Torras, Marcal Pastor-Anglada, Tatsuhiko Furukawa, Takeda Yasuo
Format: Article
Language:English
Published: Elsevier 2015-03-01
Series:Journal of Pharmacological Sciences
Subjects:
Gemcitabine
Pancreatic cancer
Anticancer agent resistance
Nucleoside transporter
Ribonucleotide reductase
Online Access:http://www.sciencedirect.com/science/article/pii/S1347861315000092

Internet

http://www.sciencedirect.com/science/article/pii/S1347861315000092

Similar Items